Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs is fully dedicated to accelerating the research and discovery of the target CD28 through the provision of premium, advanced recombinant antibodies specifically engineered for this purpose. Developed with innovative technology, our products deliver exceptional reliability and performance, meeting the needs of researchers worldwide. By supplying these top-tier antibodies, we strive to empower impactful scientific breakthroughs and drive progress in the field of biomedical research, particularly in studies focusing on the critical role of CD28.
CD28 is an essential surface molecule predominantly found on T cells, functioning as a key co-stimulatory receptor. It plays a significant role in promoting T cell activation, proliferation, and survival by interacting with ligands on antigen-presenting cells to deliver critical signals. This interaction is fundamental to regulating immune responses. Research into CD28 is immensely valuable, offering insights into the intricate mechanisms of immune regulation and the maintenance of immune balance. Understanding CD28's role provides a deeper perspective on the development of immune disorders, such as autoimmune diseases and immunodeficiencies. Furthermore, CD28 is a promising target in immunotherapy, as modulating its pathways could pave the way for innovative treatments for cancer and other immune-related conditions.
CD28 molecule; Tp44; IMD123
Enables protein kinase binding activity. Acts upstream of or within several processes, including positive regulation of immune response; positive regulation of intracellular signal transduction; and regulation of lymphocyte activation. Located on the external side of the plasma membrane and immunological synapse. Human ortholog(s) of this gene are implicated in multiple sclerosis and type 1 diabetes mellitus. Orthologous to human CD28 (CD28 molecule).
We are dedicated to accelerating research and discovery by providing high-quality anti-CD28 recombinant antibody products at an outstanding value, complemented by excellent technical support.
Cat. No. | Product Name | Target Species | Host Species | Applications |
TAB-064LC | Anti-Human CD28 Recombinant Antibody (TGN1412) | Human | Human | ELISA; Stim |
TAB-H46 | Humanized Anti-CD28 Recombinant Antibody (clone Lulizumab) | Human | Human | IP; IF; FuncS; FC; Neut; ELISA; IHC |
PABX-031 | Recombinant Mouse Anti-CD28 Antibody (5.11A1) | Human | Mouse | WB; ELISA; FuncS; Activ |
TAB-065LC | Human Anti-CD28 Recombinant Antibody | Human | Human | ELISA |
HPAB-0132CQ | Human Anti-CD28 Recombinant Antibody (clone FR255734) | Human | Human | ELISA; IHC; Block; FuncS |
We have established a robust quality management system to ensure the excellence of our products and help our customers streamline drug development by meeting and exceeding their expectations.
Fig.1 SDS-PAGE analysis of anti-CD28 antibody
(Cat# TAB-064LC, Creative Biolabs).
Fig.2 SEC-HPLC analysis of anti-CD28 antibody
(Cat# TAB-064LC, Creative Biolabs).
Fig.3 ELISA analysis of anti-CD28 antibody
(Cat# TAB-064LC, Creative Biolabs).
Fig.4 WB analysis of anti-CD28 antibody
(Cat# TAB-064LC, Creative Biolabs).
Our services encompass the entire process, from gene synthesis to the production of high-quality recombinant antibodies, ensuring a seamless experience for our customers. With this foundation, we are well-equipped to deliver outstanding antibody production solutions tailored to the needs of research specialists.
Featured Anti-CD28 Recombinant Antibody Production Platforms
Fig.5 Milligram-scale recombinant antibody production.
Fig.6 Gram-scale recombinant antibody production
Creative Biolabs is dedicated to offering researchers an extensive selection of advanced, high-quality recombinant antibodies in various formats. These formats encompass full-length antibodies, scFv, Fab, scFab, Fc fusion proteins, and more, ensuring diverse options to meet specific research needs.
Fig.7 Full Length Anti-CD28 Recombinant Antibody Production and Modalities
Table 1. Therapeutic approaches targeting CD28 in clinical development.
Research phase | Company | Classification | Indications | Details |
Launched - 2021 |
Bristol-Myers Squibb Celgene |
Biologics |
Acute lymphocytic leukemia; B-cell chronic lymphocytic leukemia |
It is an autologous anti-CD19 CAR T-cell immunotherapy developed by Bristol-Myers Squibb (formerly Celgene). |
Launched - 2020 | Kite Pharma | Biologics |
B-cell acute lymphocytic leukemia; Chronic lymphocytic leukemia |
This is an autologous anti-CD19 CAR T-cell therapy developed by Kite Pharma (a Gilead company), first launched in the U.S. |
Launched - 2017 |
Adimab Daiichi Sankyo |
Biologics |
Acute lymphocytic leukemia; B-cell acute lymphocytic leukemia |
It consists of autologous peripheral blood lymphocytes transduced with a chimeric antigen receptor (CAR) against CD19 developed by Kite Pharma (a Gilead company). |
Pre-Registered | Atox Bio | Peptides |
Acute kidney injury; Avian influenza; Immunological Disorders |
It is an immunomodulator peptide targeting the CD28 co-stimulatory receptor, currently under regulatory review in the U.S. for the treatment of suspected organ dysfunction or failure. |
Phase II |
AbbVie Alpine Immune Sciences |
Biologics |
Arthritis; Autoimmune disease |
It is a first-in-class dual ICOS/CD28 antagonist in phase II clinical development at AIS Operating (formerly, Alpine Immune Sciences) for the treatment of adults with moderate to severe active systemic lupus erythematosus (SLE). |
Phase II | Bristol-Myers Squibb | Biologics | Systemic lupus erythematosus | It is a human domain antibody targeting human CD28. The product had been evaluated in phase II clinical trials at Bristol-Myers Squibb for the treatment of systemic lupus erythematosus; however, no recent development has been reported. |
Phase II |
TeGenero TheraMAB |
Biologics | Autoimmune disease | It is a humanized superagonistic anti-CD28 monoclonal antibody that completed phase II development at TheraMAB for the treatment of adult patients with active systemic lupus erythematosus not adequately controlled with current concomitant treatment. |
Phase I/II | Regeneron | Biologics | Cancer | This is a bispecific monoclonal antibody targeting CD28 and epidermal growth factor receptor, is in early clinical development at Regeneron for the treatment of adult patients with advanced solid tumors that are naïve to anti-PD-1/PD-L1 therapies in combination with cemiplimab. |
Phase I/II | Regeneron | Biologics | Cancer | It is a bispecific antibody targeting prostate-specific membrane antigen (PSMA) and CD28 in phase I/II clinical development at Regeneron for the treatment of patients with metastatic, castration-resistant prostate cancer (mCRPC) in combination with cemiplimab. |
Phase I/II | Memorial Sloan-Kettering Cancer Center | Biologics | Cancer | It is a cell therapy consisting of T cells targeting human mesothelin (MSLN), is undergoing early clinical evaluation at the Memorial Sloan-Kettering Cancer Center for the treatment of patients with malignant pleural disease. |
Phase I | Alpine Immune Sciences | Biologics | Cancer | It is a PD-L1/CTLA-4 antagonist and PD-L1-dependent CD28 T cell costimulatory, is in early clinical development at AIS Operating (formerly, Alpine Immune Sciences) for the treatment of patients with advanced solid tumors or lymphomas. |
For more details about our anti-CD28 recombinant antibody products, please don’t hesitate to Contact us. Our team is eager to provide you with the information you need and looks forward to establishing a mutually beneficial partnership that will enhance your research efforts and drive scientific progress.